摘要
目的探讨LDHA在乳腺癌中的表达、临床意义及与SUMO1修饰的关系。方法采用免疫组化和Western blot法检测乳腺癌组织中LDHA蛋白表达,并分析其与临床病理特征的关系。应用数据库预测LDHA表达与患者预后的关系。Co-IP鉴定LDHA分子SUMO化水平,软件筛选SUMO化位点。结果LDHA在癌旁正常乳腺组织、普通型导管增生、导管不典型增生、导管原位癌和浸润性导管癌组织中的阳性率分别为26.0%、26.8%、31.4%、54.2%、64.3%。LDHA表达与乳腺癌组织学高分级、淋巴结转移、TNM III+IV期、ER阴性相关(P均<0.05),与患者总生存期、无瘤生存期呈负相关(P=0.009,P=0.008)。LDHA与SUMO1相互作用,致使乳腺癌中的SUMO化修饰水平降低。LDHA的SUMO化位点可信度最高的是K284、K59及K14。结论LDHA高表达提示乳腺癌变、恶性进展及预后不良,同时LDHA蛋白发生SUMO化修饰。
Purpose To analyse the expression of LDHA in breast carcinoma and to investigate the clinical significance and SUMO1 modification of LDHA in breast cancer.Methods The expression of LDHA protein in breast cancer tissues was detected by immunohistochemistry and Western blot,and its relationship with clinicopathological features was analyzed.The database predicted the relationship between LDHA and prognosis.Co-IP was used to identify the SUMOylation level of LDHA and software screened the SUMOylation sites.Results The positive rates of LDHA expression were 26.0%,26.8%,31.4%,54.2%and 64.3%in adjacent normal breast tissue,usual ductal hyperplasia,atypical ductal hyperplasia,ductal carcinoma in situ and invasive ductal carcinoma,respectively.The expression of LDHA was significantly associated with high grade,lymph node metastasis,TNM III+IV stage,ER negative(P<0.05)and was negatively correlated with overall survival,disease-free survival(P=0.009,P=0.008).LDHA interacted with SUMO1,and its SUMOylation level was significantly reduced in breast cancer.The SUMOylation sites of LDHA with the highest reliability were K284,K59 and K14(P<0.05).Conclusion The high expression of LDHA may indicates breast cancer transformation,malignant progression and poor prognosis,and LDHA protein may undergo SUMOylation modification.
作者
赵雪可
李威
刘文
黄泽翎
曹鸽
梁伟华
曹玉文
ZHAO Xue-ke;LI Wei;LIU Wen;HUANG Ze-ling;CAO Ge;LIANG Wei-hua;CAO Yu-wen(Department of Pathology,Medicine College of Shihezi University,Shihezi 832000,China;Department of Pathology,Shandong Second Provincial General Hospital/Shandong Provincial ENT Hospital,Jinan 250022,China;Department of Medical Ultrasound,the First Affiliated Hospital,Medicine College of Shihezi University,Shihezi 832000,China;Department of Pathology,the First Affiliated Hospital,Medicine College of Shihezi University,Shihezi 832000,China)
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2022年第4期427-431,共5页
Chinese Journal of Clinical and Experimental Pathology
基金
国家自然科学基金(81860498)。
